Stay updated on SAGE-217 for Severe Depression Clinical Trial
Sign up to get notified when there's something new on the SAGE-217 for Severe Depression Clinical Trial page.

Latest updates to the SAGE-217 for Severe Depression Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe page has changed from a 403 error screen to the full record for a Phase 2 study of SAGE-217 for major depressive disorder, including study design, eligibility, outcomes, publications, and study documents.SummaryDifference100%

- Check15 days agoChange DetectedThe footer revision changes from v3.7.2 to v3.8.0; the page continues to display a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check22 days agoChange DetectedA sitewide NIH notice announces a transition in terminology, saying federal agencies are using “Super Intelligence” in place of “Artificial Intelligence” under Executive Order 14434.SummaryDifference1%

- Check29 days agoChange DetectedThe footer revision identifier changes from v3.7.1 to v3.7.2 on the ClinicalTrials.gov 403 error page. The displayed error content and layout remain unchanged.SummaryDifference0.2%

- Check36 days agoChange DetectedThe footer revision label was updated from v3.7.0 to v3.7.1. The page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check50 days agoChange DetectedThe study page now shows a 403 Forbidden error, blocking access to the record. The page displays the standard header and footer while the main content area shows the access-denied message.SummaryDifference0.5%

Stay in the know with updates to SAGE-217 for Severe Depression Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SAGE-217 for Severe Depression Clinical Trial page.